PERCISTence: Strength or Stubbornness?

> History is the unfolding of miscalculation. > > —Barbara W. Tuchman, American historian In celebrating 60 years of JNM, it is hard to conceive of molecular imaging without 18F-FDG PET, particularly in oncology. Recognizing the importance of metabolic reprogramming in malignant transformation

• Publication year

  2020

• Venue

  Journal of Nuclear Medicine

• Publication date

  2020-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.120.250563PMID 33293440
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Does PET SUV Harmonization Affect PERCIST Response Classification?

  2016cited by this paper
• Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

  2014cited by this paper
• Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.

  2012cited by this paper
• Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Cancer clinical trial outcomes: any progress in tumour-size assessment?

  2009cited by this paper
• Optimising the design of phase II oncology trials: the importance of randomisation.

  2009cited by this paper
• Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

  2009cited by this paper
• Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma

  2009cited by this paper
• Evaluation of lymph nodes with RECIST 1.1.

  2009cited by this paper
• Follow-up of hepatic and peritoneal metastases of gastrointestinal tumors (GIST) under Imatinib therapy requires different criteria of radiological evaluation (size is not everything!!!).

  2009cited by this paper
• Individual patient data analysis to assess modifications to the RECIST criteria.

  2009cited by this paper
• Lessons learned from independent central review.

  2009cited by this paper
• From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

  2009cited by this paper
• [Gastrointestinal stromal tumors: role of computed tomography before and after treatment].

  2008cited by this paper
• Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

  2008cited by this paper
• The Lessons of GIST — PET and PET / CT : A New Paradigm for Imaging

  2008cited by this paper
• Time and Again, Children Resemble Their Parents

  2008cited by this paper
• FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma

  2008cited by this paper
• Metabolic Tumor Width Parameters as Determined on PET/CT Predict Disease-free Survival and Treatment Response in Squamous Cell Carcinoma of the Esophagus

  2008cited by this paper
• Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.

  2008cited by this paper
• Combined Assessment of Metabolic and Volumetric Changes for Assessment of Tumor Response in Patients with Soft-Tissue Sarcomas

  2008influential reference
• Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT

  2008cited by this paper
• Selection of response criteria for clinical trials of sarcoma treatment.

  2008cited by this paper
• 2-Deoxy-2[F-18]FDG-PET for Detection of Recurrent Laryngeal Carcinoma after Radiotherapy: Interobserver Variability in Reporting

  2008cited by this paper
• 18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy

  2008cited by this paper
• Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study

  2008cited by this paper
• Sorafenib in advanced hepatocellular carcinoma.

  2008cited by this paper
• The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials

  2008influential reference
• Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors

  2008influential reference
• Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.

  2007influential reference
• Efficacy of Preoperative Combined 18-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography for Assessing Primary Rectal Cancer Response to Neoadjuvant Therapy

  2007influential reference
• Assessment of tumor response in malignant pleural mesothelioma.

  2007cited by this paper
• Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.

  2007cited by this paper
• Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans

  2007influential reference
• We should desist using RECIST, at least in GIST.

  2007influential reference
• Early therapeutic response assessment by 18FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: Isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007influential reference
• FDG PET in lymphoma: The need for standardization of interpretation. An observer variation study

  2007cited by this paper
• Observer Variation of 2-Deoxy-2-[F-18]fluoro-d-Glucose-Positron Emission Tomography in Mediastinal Staging of Non-Small Cell Lung Cancer as a Function of Experience, and its Potential Clinical Impact

  2007cited by this paper
• Overview of early response assessment in lymphoma with FDG-PET

  2007cited by this paper
• Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

  2007influential reference
• The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007influential reference
• Monitoring cancer treatment with PET/CT: does it make a difference?

  2007cited by this paper
• Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

  2007influential reference
• Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.

  2007cited by this paper
• Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.

  2006cited by this paper
• Monitoring chemotherapy and radiotherapy of solid tumors

  2006cited by this paper
• FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

  2006cited by this paper
• 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.

  2006cited by this paper
• Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery.

  2006cited by this paper
• Positron emission tomography as an imaging biomarker.

  2006cited by this paper
• FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer

  2006cited by this paper
• Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.

  2006influential reference
• Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.

  2006cited by this paper
• RECIST revisited: a review of validation studies on tumour assessment.

  2006cited by this paper
• Measuring response in a post-RECIST world: from black and white to shades of grey

  2006cited by this paper
• Significant clinical impact and prognostic stratification provided by FDG-PET in the staging of oesophageal cancer

  2006cited by this paper
• Positron-emission tomography and assessment of cancer therapy.

  2006cited by this paper
• Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer.

  2006cited by this paper
• Value of 18F-Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography/Computed Tomography in Non–Small-Cell Lung Cancer for Prediction of Pathologic Response and Times to Relapse after Neoadjuvant Chemoradiotherapy

  2006cited by this paper
• Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy.

  2006cited by this paper
• Limitations with the response evaluation criteria in solid tumors (RECIST) guidance in disseminated pediatric malignancy

  2006cited by this paper
• The paradox of response and survival in cancer therapeutics.

  2006cited by this paper
• Predictive Value of 18-Fluoro-Deoxy-Glucose-Positron Emission Tomography (18F-FDG-PET) in the Identification of Responders to Chemoradiation Therapy for the Treatment of Locally Advanced Esophageal Cancer

  2006cited by this paper
• Assessment of tumor response on MR imaging after locoregional therapy.

  2006cited by this paper
• Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.

  2005cited by this paper
• EXPRESSION OF UBIQUITIN-SPECIFIC PROTEASE 14 IN HUMAN PANCREATIC CANCER CELL LINES AND CANCER TISSUES

  2005cited by this paper
• Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography.

  2005cited by this paper
• Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

  2005cited by this paper
• Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma.

  2005cited by this paper
• Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.

  2005cited by this paper
• Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development

  2005cited by this paper
• The role of PET in monitoring therapy

  2005cited by this paper
• Use of PET for monitoring cancer therapy and for predicting outcome.

  2005cited by this paper
• Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.

  2005cited by this paper
• Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial

  2005influential reference
• [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.

  2005cited by this paper
• Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues.

  2004cited by this paper
• The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors.

  2004cited by this paper
• Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining longterm outcomes of rectal cancer.

  2004cited by this paper
• Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.

  2004influential reference
• Therapeutic implications of cancer stem cells.

  2004cited by this paper
• Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.

  2004influential reference
• Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.

  2004cited by this paper
• FDG PET and high-dose therapy for aggressive lymphomas: toward a risk-adapted strategy

  2004cited by this paper
• Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.

  2004cited by this paper
• 2‐Fluoro‐2‐deoxy‐D‐glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma

  2004cited by this paper
• [18F]Fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer

  2004cited by this paper
• Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer.

  2004cited by this paper
• Accuracy of the EasyTouch blood glucose self-monitoring system: a study of 516 cases.

  2004cited by this paper
• CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.

  2004influential reference
• Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation.

  2004cited by this paper
• Update of the FDG PET search strategy

  2004cited by this paper
• Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.

  2004cited by this paper
• Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.

  2004cited by this paper
• Fluorodeoxyglucose uptake in the aortic wall at PET/CT: possible finding for active atherosclerosis.

  2003cited by this paper
• 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec).

  2003influential reference
• From PET detectors to PET scanners

  2003cited by this paper

• No citing papers are available for this paper.